Differentiation therapy for IDH1/2 mutant malignancies Academic Article uri icon

Overview

MeSH Major

  • DNA Methylation
  • Epigenesis, Genetic
  • Software

abstract

  • Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3731561

Digital Object Identifier (DOI)

  • 10.1038/cr.2013.73

PubMed ID

  • 23732524

Additional Document Info

start page

  • 975

end page

  • 7

volume

  • 23

number

  • 8